Real-world data link weekly semaglutide to lower renal risk in CKD
In Optum claims data, semaglutide beat sulfonylureas, DPP4 inhibitors and TZDs on HbA1c, weight, blood pressure and a composite kidney endpoint.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 22 20:00 ETSource: Advances in therapy
The wire
- 01Using Optum Clinformatics data from 2016 to mid-2023, adults with type 2 diabetes and CKD on once-weekly semaglutide showed 12-month advantages of 0.54% HbA1c, 6.69 kg weight, 3.63 mmHg systolic blood pressure and 2.06 mL/min/1.73 m2 eGFR versus oral comparators.
- 02The composite renal outcome of dialysis, transplant, sustained eGFR under 15 or death was less frequent with semaglutide (adjusted HR 0.78, 95% CI 0.62-0.99), relevant for patients ineligible for or failing SGLT2 inhibitors.
- 03This is a retrospective claims analysis subject to confounding by indication, not a randomized trial, and the confidence interval for the renal outcome sits close to 1.
From the source
Read at pubmed.ncbi.nlm.nih.govComparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease
Advances in therapy · 2026 Sep 23 · Amamoo J, Wang Y, Liu H et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42776473/
